CONNEQT Health Unveils Share Purchase Plan to Accelerate Business Expansion
CONNEQT Health Limited (ASX: CQT) has launched a Share Purchase Plan (SPP) that enables eligible shareholders in Australia and New Zealand to subscribe for up to AU$30,000 of new shares without brokerage costs. The company aims to secure around AU$0.5 million through the offer, while retaining the flexibility to adjust the final amount raised depending on shareholder demand. The proceeds are intended to strengthen inventory levels, advance product innovation, expand intellectual property, enhance commercial activities, and support ongoing business development. A portion of the funds will also be allocated to working capital and regulatory initiatives as the company continues to broaden its healthcare technology portfolio. The SPP gives retail investors the opportunity to participate on terms consistent with the recent institutional placement. Scheduled to close on 24 July 2026, the capital raising is expected to provide additional financial resources to support CONNEQT Health's long-term commercial growth strategy.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
CONNEQT Health Unveils Share Purchase Plan to Accelerate Business Expansion
CONNEQT Health Limited (ASX: CQT) has launched a Share Purchase Plan (SPP) that enables eligible shareholders in Australia and New Zealand to subscribe for up to AU$30,000 of new shares without brokerage costs. The company aims to secure around AU$0.5 million through the offer, while retaining the flexibility to adjust the final amount raised depending on shareholder demand. The proceeds are intended to strengthen inventory levels, advance product innovation, expand intellectual property, enhance commercial activities, and support ongoing business development. A portion of the funds will also be allocated to working capital and regulatory initiatives as the company continues to broaden its healthcare technology portfolio. The SPP gives retail investors the opportunity to participate on terms consistent with the recent institutional placement. Scheduled to close on 24 July 2026, the capital raising is expected to provide additional financial resources to support CONNEQT Health's long-term commercial growth strategy.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au